Invasive apocrine carcinoma of the breast—a surgeon’s perspective on diagnosis, pitfalls, and evolving management options

TL;DR

This paper discusses a rare breast cancer type, its diagnosis challenges, and treatment options from a surgeon's viewpoint.

Contribution

The paper highlights practical insights into managing invasive apocrine carcinoma from a surgeon's perspective.

Findings

Invasive apocrine carcinoma often shows ER/PR/HER2 negativity and strong androgen receptor expression.

Breast-conserving surgery with clear margins and negative sentinel nodes can be effective for this subtype.

AR-directed therapies and genomic approaches are emerging as potential treatment options.

Abstract

Invasive apocrine carcinoma (IAC) is a rare histologic subtype of breast carcinoma that commonly shows an ER/PR/HER2 triple negative phenotype with strong androgen receptor (AR) expression. We report a case of a 58 year old woman with an incidentally detected left breast lesion, treated with breast conserving surgery and sentinel lymph node biopsy. Final pathology revealed a 1.7 × 1 × 1 cm invasive carcinoma with apocrine morphology, clear margins and five negative sentinel nodes; IHC showed ER/PR/HER2 negativity, AR strongly positive (90%), and low proliferation (Ki-67 8%). The patient received whole breast radiotherapy followed by systemic chemotherapy with paclitaxel and carboplatin. This report emphasizes diagnostic pitfalls (including positron emission tomography limitations and cytology traps), practical intraoperative decision-making, axillary management tailored to indolent biology, and the emerging role of AR directed and genomic guided therapies from a surgeon’s viewpoint. Awareness of these issues helps avoid overtreatment while preserving options for targeted systemic approaches.

Figures